

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 December 2024 (05.12.2024)



(10) International Publication Number
WO 2024/249299 A3

(51) International Patent Classification:

C07D 487/22 (2006.01) A61K 31/504 (2006.01)
C07D 487/14 (2006.01) A61K 35/00 (2006.01)
C07D 519/00 (2006.01)

(21) International Application Number:

PCT/US2024/030993

(22) International Filing Date:

24 May 2024 (24.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/469,283 26 May 2023 (26.05.2023) US

(71) Applicant: **REVOLUTION MEDICINES, INC.**

[US/US]; 700 Saginaw Drive, Redwood City, CA 94063 (US).

(72) Inventors: **KNOX, John E.**; Revolution Medicines, Inc.,

700 Saginaw Drive, Redwood City, CA 94063 (US). **KOLTUN, Elena S.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **PARSONS, Dylan E.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **TOMLINSON, Aidan**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **BURNETT, G. Leslie**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **CREGG, James**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **GILL, Adrian L.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **BUCKL, Andreas**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael J.** et al.; Clark & Elbing

LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

03 April 2025 (03.04.2025)

(54) Title: RAS INHIBITORS

(57) Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.



WO 2024/249299 A3